Nature's Sunshine Products Inc (NATR): Net Income
$20.45M
Year ended 2025-12-31
$18.70M
Trailing 12 months to 2026-06-30
+233.8%
3-year compound annual growth
-2.3%
5-year compound annual growth
+4.1%
10-year compound annual growth
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.45M | +159.1% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $7.89M | -51.9% | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $16.42M | n/m | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | $550.0K | -98.2% | 2024-03-12, From 2022-01-01 |
| 2021-12-31 | $30.21M | +31.6% | 2023-03-16, From 2021-01-01 |
| 2020-12-31 | $22.96M | +231.3% | 2022-03-08, From 2020-01-01 |
| 2019-12-31 | $6.93M | n/m | 2021-03-10, From 2019-01-01 |
| 2018-12-31 | -$1.20M | n/m | 2020-03-11, From 2018-01-01 |
| 2017-12-31 | -$13.82M | n/m | 2019-03-08, From 2017-01-01 |
| 2016-12-31 | $675.0K | -95.1% | 2019-03-08, From 2016-01-01 |
| 2015-12-31 | $13.66M | +39.3% | 2018-03-16, From 2015-01-01 |
| 2014-12-31 | $9.80M | -44.3% | 2017-03-14, From 2014-01-01 |
| 2013-12-31 | $17.61M | -30.6% | 2016-03-14, From 2013-01-01 |
| 2012-12-31 | $25.38M | n/a | 2015-03-13, From 2012-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $20.45M | +159.1% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | -$25.55M | n/m |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | -$732.94M | n/m |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | -$175.54M | n/m |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | -$23.36M | n/m |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $456.91M | n/m |
| Innoviva, Inc. (INVA) | 2025-12-31 | $271.17M | n/m |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $37.03M | n/m |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | -$61.60M | n/m |
Compare NATR, TVTX, BBIO, ZLAB side by side · Screen every company in Pharmaceutical Preparations ↗